Lupus & antiphospholipid syndrome
Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY systemic lupus erythematosus (SLE) trial in patients with active systemic lupus erythematosus
Authors' conclusion
Deucravacitinib demonstrated suppression of IFN and B-cell pathway biomarkers in patients with SLE
Study context
- Population
- Patients with active SLE in the phase 2 PAISLEY SLE trialplus up to 60 healthy volunteer samples
- Participants
- 363 patients
- Comparison
- Deucravacitinib vs placebo; SLE vs healthy volunteers
Methodological detailspharmacodynamic analysis, phase 2, descriptive analyses, 51 immune system-related genes measured by chemical ligation-dependent probe amplification
- Pharmacodynamic analysis
- Phase 2
- Descriptive analyses
- 51 immune system-related genes measured by chemical ligation-dependent probe amplification
Primary result
As reported in the abstract
At screening, genes differentially expressed in SLE vs healthy volunteers
42
At screening, proteins differentially expressed in SLE vs healthy volunteers
75
Original publication
Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus. Ann Rheum Dis. Published 27 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →